🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ALK+ Non-Small-Cell Lung Carcinoma

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site📍 Beijing Peking Union Medical College Hospital · Tests: Ensartinib Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer NCT05765877Phase 21 site📍 Jinan Pingping Song · Tests: WX-0593 Tablets Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer NCT05241028Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Ensartinib Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer NCT07415005Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Lorlatinib A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib NCT06378892Phase 29 sites📍 Aviano📍 Florence📍 Lido di Camaiore Centro di Riferimento Oncologico - Aviano · Tests: Lorlatinib Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221n/a1 site📍 Aurora University of Colorado, Denver Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib NCT06620835Phase 227 sites📍 Brest📍 Caen📍 Chambéry Groupe Francais De Pneumo-Cancerologie · Tests: Blood samples for Hematology, Blood samples for Chemistry, Blood sample for liver function tests, Pregnancy test, Tumou… AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer NCT07617337Phase 17 sites📍 Houston📍 Nagoya📍 Kashiwa Chugai Pharmaceutical · Tests: AQUA07, Lorlatinib ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma NCT05014464Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Crizotinib Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC NCT05681780Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation NCT04322890Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Osimertinib, Alectinib 150 MG, Crizotinib 250 MG, Savolitinib, Crizotinib., Chemotherapy Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context NCT06487078NA32 sites📍 Toulouse📍 Paris📍 Aix-en-Provence Pfizer · Tests: Lorlatinib Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC NCT05122806NA46 sites📍 Saint-Denis📍 Aix-en-Provence📍 Amiens Groupe Francais De Pneumo-Cancerologie · Tests: RNAseq Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006Phase 1, Phase 21 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Alectinib Oral Product Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC NCT05950139Phase 1, Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Peptide vaccine A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647Phase 3300 sites📍 Mobile📍 Chandler📍 Phoenix AstraZeneca · Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels NCT05525338Phase 48 sites📍 Villejuif📍 Nijmegen📍 Maastricht University Medical Center Groningen · Tests: Alectinib A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) NCT07140016Phase 117 sites📍 Fullerton📍 Orange📍 Edwards Astellas Pharma Global Development, Inc. · Tests: gilteritinib Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy NCT06862869n/a44 sites📍 Zhanjiang📍 Guangzhou📍 Kaifeng Hoffmann-La Roche · Tests: Alectinib Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels NCT07360743Phase 24 sites📍 Bordeaux📍 Boulogne-Billancourt📍 Nice UNICANCER · Tests: Pembrolizumab, Cemiplimab Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935NA1 site📍 Boston Massachusetts General Hospital · Tests: POISE A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma NCT05456256Phase 216 sites📍 Beverly Hills📍 Fountain Valley📍 Los Alamitos Lantern Pharma Inc. · Tests: LP-300, Pemetrexed, Carboplatin Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression NCT05777278Phase 1, Phase 21 site📍 Guangzhou The First Affiliated Hospital of Guangzhou Medical Universi… · Tests: Savolitinib, Docetaxel Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer NCT05284539Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC NCT06092086Phase 21 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Loratinib A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) NCT05724004NA1 site📍 Stockholm Karolinska University Hospital · Tests: SBRT/SRS/radiation therapy Gilteritinib for the Treatment of ALK NSCLC NCT06225427Phase 13 sites📍 Los Angeles📍 Washington D.C.📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients NCT06361589n/a1 site📍 Chengdu Sichuan Cancer Hospital and Research Institute · Tests: Lorlatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy